KRAS and lung adenocarcinoma: This case reports a patient with stage IV lung adenocarcinoma treated with a combination of an antiangiogenic inhibitor and an immune checkpoint inhibitor who switched from a combination of camrelizumab and endonuclease to a combination of camrelizumab and bevacizumab with a sustained benefit over 18 months, suggesting that combination immunotherapy may be a treatment option for patients with KRAS mutations in advanced non‐small cell lung cancer.